Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

X **e, T Yu, X Li, N Zhang, LJ Foster, C Peng… - Signal transduction and …, 2023 - nature.com
Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

Targeting oncogenic Myc as a strategy for cancer treatment

H Chen, H Liu, G Qing - Signal transduction and targeted therapy, 2018 - nature.com
The MYC family oncogene is deregulated in> 50% of human cancers, and this deregulation
is frequently associated with poor prognosis and unfavorable patient survival. Myc has a …

Overview and recent advances in the treatment of neuroblastoma

SB Whittle, V Smith, E Doherty, S Zhao… - Expert review of …, 2017 - Taylor & Francis
Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from
cure in> 90% of patients with low risk disease to< 50% for those with high risk disease …

Neuroblastoma: clinical and biological approach to risk stratification and treatment

VP Tolbert, KK Matthay - Cell and tissue research, 2018 - Springer
Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most
common in the first year of life. It is a unique malignancy in that infants often present with …

ATR/CHK1 inhibitors and cancer therapy

Z Qiu, NL Oleinick, J Zhang - Radiotherapy and Oncology, 2018 - Elsevier
The cell cycle checkpoint proteins ataxia-telangiectasia-mutated-and-Rad3-related kinase
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …

Neuroblastoma and MYCN

M Huang, WA Weiss - Cold Spring …, 2013 - perspectivesinmedicine.cshlp.org
Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to
originate from undifferentiated neural crest cells. Amplification of the MYC family member …

MYC and therapy resistance in cancer: risks and opportunities

G Donati, B Amati - Molecular oncology, 2022 - Wiley Online Library
The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …

Roles of Chk1 in cell biology and cancer therapy

Y Zhang, T Hunter - International journal of cancer, 2014 - Wiley Online Library
The evolutionally conserved DNA damage response (DDR) and cell cycle checkpoints
preserve genome integrity. Central to these genome surveillance pathways is a protein …

The expanding world of N-MYC–driven tumors

DS Rickman, JH Schulte, M Eilers - Cancer discovery, 2018 - aacrjournals.org
Enhanced and deregulated expression of N-MYC, a member of the MYC family of
transcription factors, drives the development of multiple tumors, including tumors of the …

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma

JA Rader, MR Russell, LS Hart… - Clinical cancer …, 2013 - aacrjournals.org
Purpose: Neuroblastoma is a pediatric cancer that continues to exact significant morbidity
and mortality. Recently, a number of cell-cycle proteins, particularly those within the Cyclin …